It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Over 15% of probands in a large cohort of more than 1500 inherited retinal degeneration patients present with a clinical diagnosis of Stargardt disease (STGD1), a recessive form of macular dystrophy caused by biallelic variants in the ABCA4 gene. Participants were clinically examined and underwent either target capture sequencing of the exons and some pathogenic intronic regions of ABCA4, sequencing of the entire ABCA4 gene or whole genome sequencing. ABCA4 c.4539 + 2028C > T, p.[= ,Arg1514Leufs*36] is a pathogenic deep intronic variant that results in a retina-specific 345-nucleotide pseudoexon inclusion. Through analysis of the Irish STGD1 cohort, 25 individuals across 18 pedigrees harbour ABCA4 c.4539 + 2028C > T and another pathogenic variant. This includes, to the best of our knowledge, the only two homozygous patients identified to date. This provides important evidence of variant pathogenicity for this deep intronic variant, highlighting the value of homozygotes for variant interpretation. 15 other heterozygous incidents of this variant in patients have been reported globally, indicating significant enrichment in the Irish population. We provide detailed genetic and clinical characterization of these patients, illustrating that ABCA4 c.4539 + 2028C > T is a variant of mild to intermediate severity. These results have important implications for unresolved STGD1 patients globally with approximately 10% of the population in some western countries claiming Irish heritage. This study exemplifies that detection and characterization of founder variants is a diagnostic imperative.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Trinity College Dublin, The School of Genetics and Microbiology, Dublin 2, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705)
2 Trinity College Dublin, The School of Genetics and Microbiology, Dublin 2, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705); The Mater Misericordiae University Hospital, Next Generation Sequencing Laboratory, Pathology Department, Dublin 7, Ireland (GRID:grid.411596.e) (ISNI:0000 0004 0488 8430)
3 Royal Victoria Eye and Ear Hospital, Department of Ophthalmology, Dublin 2, Ireland (GRID:grid.416227.4) (ISNI:0000 0004 0617 7616); The Mater Misericordiae University Hospital, Mater Clinical Ophthalmic Genetics Unit, Dublin 7, Ireland (GRID:grid.411596.e) (ISNI:0000 0004 0488 8430)
4 The Mater Misericordiae University Hospital, Mater Clinical Ophthalmic Genetics Unit, Dublin 7, Ireland (GRID:grid.411596.e) (ISNI:0000 0004 0488 8430)
5 Radboud University Medical Center, Department of Human Genetics, Nijmegen, the Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382); Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands (GRID:grid.419550.c) (ISNI:0000 0004 0501 3839); International Max Planck Research School for Language Sciences, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands (GRID:grid.419550.c) (ISNI:0000 0004 0501 3839)
6 Radboud University Medical Center, Department of Human Genetics, Nijmegen, the Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382); Academic Alliance Genetics, Radboud University Medical Center, Nijmegen, and Maastricht University Medical Center+, Maastricht, The Netherlands (GRID:grid.412966.e) (ISNI:0000 0004 0480 1382)
7 Royal Victoria Eye and Ear Hospital, Department of Ophthalmology, Dublin 2, Ireland (GRID:grid.416227.4) (ISNI:0000 0004 0617 7616)
8 The Mater Misericordiae University Hospital, Mater Clinical Ophthalmic Genetics Unit, Dublin 7, Ireland (GRID:grid.411596.e) (ISNI:0000 0004 0488 8430); International Max Planck Research School for Language Sciences, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands (GRID:grid.419550.c) (ISNI:0000 0004 0501 3839); The Mater Misericordiae University Hospital, National Centre for Inherited Metabolic Disorders, Dublin 7, Ireland (GRID:grid.411596.e) (ISNI:0000 0004 0488 8430); Trinity College Dublin, School of Medicine, Dublin 2, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705)
9 Queen’s University Belfast, Centre for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); University College Dublin, School of Medicine, Dublin 4, Ireland (GRID:grid.7886.1) (ISNI:0000 0001 0768 2743); The Royal Victoria Hospital, Department of Ophthalmology, Belfast, UK (GRID:grid.416232.0) (ISNI:0000 0004 0399 1866)
10 Trinity College Dublin, The School of Genetics and Microbiology, Dublin 2, Ireland (GRID:grid.8217.c) (ISNI:0000 0004 1936 9705); Royal Victoria Eye and Ear Hospital, Department of Ophthalmology, Dublin 2, Ireland (GRID:grid.416227.4) (ISNI:0000 0004 0617 7616)